NeuroPace Inc Dossier - Source-backed chat

NeuroPace Inc

NPCENASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.61

Intrinsic Value $12.57median of 2 methodsbased on filings through 30 Jun 2026

Market Price $13.15Price as of 1 Oct 2026

Near fair valueIntrinsic value is 4% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $451.4M

Enterprise Value $497.8M

Shares Outstanding 34.5M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NeuroPace is a highly innovative medical technology company leading the brain-responsive neuromodulation market for drug-resistant epilepsy. The core investment thesis centers on the robust commercial momentum of its flagship RNS System, expanding clinical indications into Idiopathic Generalized Epilepsy (IGE), and the introduction of AI-driven clinical decision tools like the newly approved ECoG Assistant. While the company remains in a pre-profit growth phase with ongoing net losses, its high gross margins (exceeding 80%), raised full-year 2026 guidance, and strategic divestiture of the lower-margin DIXI Medical distribution business position it for accelerated operating leverage and long-term value creation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$20.00

High · most bullish analyst$22.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.0020%

Regulatory delays in the approval of the NAUTILUS PMA supplement push the IGE launch into late 2027. Fayer coverage expansion and reimbursement adoption for new indications are slower than expected, while increased commercial investments in salesforce expansion and nurse navigators pressure near-term cash reserves, requiring dilutive capital raises.

Base CaseCentral scenario

$20.0050%

Matches the consensus mean

Steady execution of the core RNS business with underlying growth of 21% to 23% in 2026, achieving full-year revenue of $99 million to $101 million. Gross margins remain stable between 81.5% and 82.5%. The NAUTILUS PMA supplement for IGE is approved in mid-to-late 2026, with commercial contributions beginning to scale in 2027. Operating losses continue to narrow gradually.

Bull CaseUpside scenario

$22.0030%

Rapid market penetration driven by expanding community referral networks and Level 4 Comprehensive Epilepsy Centers. Early FDA approval and swift commercial adoption of the IGE indication (NAUTILUS study) in late 2026, combined with high physician uptake of the AI-driven ECoG Assistant, accelerates revenue growth beyond 25% annually, leading to accelerated profitability and positive cash flow.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong core RNS System sales growth (19.5% YoY in Q1 2026) supported by record active prescribers and patient pipelines.
Industry-leading gross margins (82.5% non-GAAP in Q1 2026) providing significant potential for operating leverage.
Imminent catalyst from the potential FDA approval of the NAUTILUS PMA supplement for Idiopathic Generalized Epilepsy (IGE) in mid-2026.
First-mover advantage in AI-driven epilepsy care with the FDA approval of ECoG Assistant in May 2026.

Key Investment Risks

Ongoing net losses ($6.7 million GAAP net loss in Q1 2026) and negative free cash flows.
Regulatory and adoption risks associated with the new IGE indication and AI tools.
Commercial execution risks as the company expands its salesforce and community referral networks.
Potential need for future capital raises if path to profitability is delayed.

Thesis Invalidation Triggers

FDA rejection or significant delay of the NAUTILUS PMA supplement for the IGE indication.
A sharp decline in RNS System adoption rates or loss of active prescribing accounts.
Severe gross margin compression below 75% due to pricing pressures or manufacturing inefficiencies.
Inability to successfully transition DIXI Medical operations, leading to unexpected financial liabilities.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.